Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Bubs Australia Ltd. ( (AU:BUB) ).
Bubs Australia says the US Food and Drug Administration is continuing its review of the company’s New Infant Formula Submissions for its Bubs Essential, Bubs 365 Day Grass Fed and Bubs Goat powder formulas, a key step in securing permanent regulatory approval and long-term market access in the United States. While the approvals process is finalised, the FDA has confirmed it will continue to allow the importation, sale and distribution of Bubs’ products under its enforcement discretion regime beyond 31 December 2025, ensuring uninterrupted supply for US retailers and families and underpinning Bubs’ ongoing push to cement its position in the US infant formula market.
The most recent analyst rating on (AU:BUB) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
More about Bubs Australia Ltd.
Bubs Australia Limited is an Australian infant nutrition company that manufactures and markets powder infant formulas, including its Bubs Essential, Bubs 365 Day Grass Fed and Bubs Goat ranges, with a strategic focus on supplying families and retail partners in the United States market.
Average Trading Volume: 1,158,004
Technical Sentiment Signal: Sell
Current Market Cap: A$120.7M
Learn more about BUB stock on TipRanks’ Stock Analysis page.